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Lentiviral vectors based on human immunodeficiency virus type 1 (HIV-1) possess the ability to deliver exogenous genes
to both dividing and nondividing cells and to subsequently establish a stable provirus in these target cells, which can allow
long-term expression of the transferred gene. Herein we describe a stable packaging cell line that is devoid of HIV-1 tat, vif,
vpr, vpu, and nef. In order to avoid any risk of cytotoxicity associated with constitutive expression of HIV-1 protease or the
VSV-G envelope protein, transcription of the packaging and envelope constructs was tightly controlled by employing the
ecdysone-inducible system. Using this cell line, we have been able to consistently generate concentrated pseudotyped
vector virus stocks with titers in the range of 108 IU/ml, which can efficiently transduce actively dividing and growth-arrested
cells in vitro. This novel packaging cell line for lentiviral vectors facilitates the production of high-titer virus stocks in the
absence of replication-competent virus and provides us with an important tool for use in future gene transfer studies. © 2001
Academic PressKey Words: HIV-1; lentiviral vector; cell line; regulated viral gene expression; inducible; ecdysone; GFP; gene therapy;
transgene; nondividing cells; HeLa cells.INTRODUCTION
Retroviral vectors are attractive as vehicles for gene
transfer because of their characteristic ability to inte-
grate into the target cell genome and to express an
exogenous gene of interest for long periods of time. To
date, most gene therapy trials have utilized vectors de-
rived from the oncoretrovirus murine leukemia virus
(MLV). However, the utility of these systems for in vivo
gene transfer is limited because the inability of the MLV
preintegration complex to traverse the nuclear envelope
precludes its efficient transduction of nondividing target
cells (Miller et al., 1990). Recently the effort to develop
improved retroviral derived gene transfer systems for in
vivo gene delivery has shifted to those based upon
lentiviruses such as the human immunodeficiency vi-
rus-1 (HIV-1) owing to their ability to stably infect nondi-
viding cells such as neurons, hepatocytes, and muscle
cells (Zufferey et al., 1997; Naldini et al., 1996a, b; Kafri et
al., 1997, 1999). In addition, pseudotyping the virions
produced from these systems with the vesicular stoma-
titis virus G protein (VSV-G) allows for a greater target
cell range and generation of high-titer viral stocks by
concentration without significant reduction in infectivity
(Burns et al., 1993).
The HIV-1 genome codes for the proteins Gag, Pol,
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (732) 235-5223. E-mail: doughejp@umdnj.edu.
77and Env, which are common to all retroviruses. In addi-
tion, it contains two regulatory genes, tat and rev, that are
important for efficient viral replication, and four acces-
sory genes, vif, vpr, vpu, and nef, that have been dem-
onstrated to be dispensable for HIV-1 vector production
from transfected cells (Kafri et al., 1997; Kim et al., 1998;
Zufferey et al., 1997). The current general method for
generating pseudotyped lentiviral vector stocks involves
transient cotransfection of (i) a packaging plasmid con-
sisting of HIV-1 gag, pol, and its regulatory and acces-
sory genes, (ii) an envelope construct encoding the
VSV-G protein, and (iii) the transfer vector that contains
the cis-acting signals required for reverse transcription
and integration as well as an exogenous gene of interest
driven by a foreign promoter. When using a transient
transfection system, however, the quality of the vector
stock produced may vary greatly and the potential for
recombination and subsequent generation of replication-
competent virus during vector production is of serious
concern. Several groups have addressed this biosafety
issue by deleting HIV-1 genes that are not required for its
production or infectivity (Gasmi et al., 1999; Sutton et al.,
1998; Kim et al., 1998) and including a self-inactivating
transfer vector (Zufferey et al., 1998; Miyoshi et al., 1998;
Dull et al., 1998). Although these systems are safer, they
still are dependent upon transient cotransfection of mul-
tiple plasmid constructs to produce vector virus. Repli-
cation-competent retrovirus could potentially arise from
such systems due to the high frequency of homologous
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78 PACCHIA ET AL.and nonhomologous recombination known to occur dur-
ing the transfection process (Mann et al., 1983).
In this report we describe the creation of a novel
stable lentiviral packaging cell line devoid of tat, vif, vpr,
vpu, and nef. Regulated expression from the packaging
construct is achieved by placing the gag, pol, and rev
genes under control of an inducible ecdysone promoter.
Incorporation of the VSV-G envelope protein and the
green fluorescent protein (GFP) into a second inducible
plasmid allows us to simultaneously pseudotype the
vector virus produced and observe the induction process
while reducing the possibility of generating replication-
competent virus. Moreover, because this cell line is sta-
ble and derived from individual clones, high-titer virus
stocks can be generated reproducibly and repeatedly,
effectively eliminating the need for subsequent transfec-
tions. The deletion of all nonessential HIV-1 proteins and
the regulation of virion production from our system pro-
vides a novel and safe means for investigating its utility
in in vivo gene therapy protocols.
RESULTS
Strategy for generation of inducible lentiviral
packaging cell line
Packaging cells based on HIV-1 have been difficult to
develop in large part due to the cytotoxicity associated
with constitutive high-level expression of the VSV-G en-
velope protein used for pseudotyping the virus to be
produced. In addition, regulated HIV-1 protease produc-
FIG. 1. Schematic diagrams of the expression plasmids and retrovira
line. pVgRXR encodes the subunits of the transcriptional heterodime
construction of pEgpr, pEcVIGhyg, and pCHSGIP are described in det
encapsidation signal downstream of the splice donor site. RSV, Ro
cytomegalovirus; Ec, inducible ecdysone promoter; VSV-G, coding sequ
ribosomal entry site from encephalomyocarditis virus (EMCV); gfp, sequ
polyadenylation signal; SV40, SV40 early gene promoter; hygro, hygrom
U3 promoter; puro, puromycin gene.tion would be beneficial since it has been reported to
have cytopathic effects and would provide an additionallevel of safety (Kaplan and Swanstrom, 1991). Employing
an inducible system allows for regulated expression of
cytotoxic proteins since their transcription occurs only
upon addition of the corresponding inducer. The tetracy-
cline-regulated system is a widely used and well-char-
acterized example of an inducible system. However, it
has been reported that high-level expression of the
transactivating fusion protein tTA can be cytotoxic
(Shockett et al., 1995; Gossen and Bujard, 1992). We
therefore selected an ecdysone-inducible expression
system to provide regulated production of all trans-acting
proteins (No et al., 1996). The system is based on the
ability of an ecdysone analog, ponasterone A, to activate
transcription through a heterodimer that has been mod-
ified to allow gene expression in mammalian cells. The
heterodimer consists of an ecdysone receptor (VgEcR)
that contains the VP16 transactivation domain from her-
pes simplex virus and its binding partner, the retinoid X
receptor (RXR). Addition of ponasterone A causes the
VgEcR/RXR heterodimer to bind to a hybrid ecdysone
response element and to activate gene transcription
from a minimal heat shock promoter through the action
of the VP16 domain contained in VgEcR.
Construction of the packaging cell line
To begin, we generated a ponasterone A-responsive
293T-based cell line that produces HIV-1 structural and
enzymatic proteins by cotransfecting the pVgRXR plas-
mid, which contains coding sequences for both the
VgEcR/RXR heterodimer and zeocin resistance, along
r used to establish the stable, inducible lentiviral vector producer cell
s shaded with diagonal lines depict nonfunctional HIV-1 genes. The
er Materials and Methods. Dc represents a 33-bp deletion within the
coma virus promoter; CMV, immediate-early promoter from human
r the G envelope protein from vesicular stomatitis virus; IRES, internal
coding the green fluorescent protein; BGH pA, bovine growth hormone





ence enwith a packaging plasmid, pEcgpr (Fig. 1). This packag-
































79LENTIVIRAL PACKAGING CELL SYSTEMscription of gag, pol, and rev by the upstream ecdysone
promoter and has deletions of tat, vif, vpr, vpu, and nef
(Fig. 1). Sixty-eight stably transfected zeocin-resistant
clones were screened for the presence of the packaging
plasmid by assaying for RT activity in the absence and
presence of ponasterone A as described under Materi-
als and Methods. We chose the cell line with the highest
level of induction and RT enzymatic activity, designated
REr1, for further development.
The envelope construct pEcVIGhyg used in the cre-
ation of the inducible packaging cell line contains coding
sequences for the VSV-G envelope protein and GFP
under transcriptional control of the inducible ecdysone
promoter as well as a gene that confers hygromycin
resistance to transfected cells (Fig. 1). An internal ribo-
somal entry site (IRES) allows translation of GFP to occur
in a cap-independent manner. REr1 cells were trans-
fected with pEcVIGhyg and selected for hygromycin re-
sistance. Thirty-eight hygromycin-resistant, nonfluoresc-
ing cell clones were induced with ponasterone A and
screened by fluorescence microscopy for induction of
GFP expression. Cell clones exhibiting the highest level
of induction and the most homogenous GFP-positive
population were chosen as putative packaging cell lines.
Because the production of reverse transcriptase and
GFP does not provide direct evidence of an individual
cell clone’s ability to package and produce virus, and
since the transient titer of a particular clone is one
indication of its ability to produce functional viral pro-
teins, we chose to evaluate the potential of each of the
clones to package and produce viable virus particles.
The above-mentioned cell clones were transiently trans-
fected with the transfer vector pCHSGIP, induced with
ponasterone A, and titered on HeLa cells according to
the protocol described under Materials and Methods.
The clone we designate as REr1.35 had the highest
transient titer among all the clones that were screened.
Accordingly, we chose to characterize this particular sta-
ble, inducible packaging cell line and evaluate its poten-
tial to become a stable, high-titer lentiviral vector pro-
ducer cell line.
The time course of inducible expression of viral pro-
teins from the REr1.35 packaging cell line was investi-
gated using three different approaches whose results
are displayed in Fig. 2. First, production of the HIV-1 gag
protein product p24 in conditioned medium was deter-
mined by enzyme-linked immunosorbent assay (ELISA).
The concentration of p24gag was found to be below the
hreshold of detection prior to addition of ponasterone A
nd reached maximal amounts 4 days postinduction (Fig.
A). Then, HIV-1 RT, a product of the pol gene, was
easured by assaying for its enzymatic activity in the
upernatant taken from REr1.35 cells before and during
nduction with ponasterone A (Fig. 2B). RT activity was
ndetectable prior to induction and was clearly present
n increasing amounts on days 1 through 4 postinduc-
e
uion. Additionally, we examined cell lysates prepared
rom REr1.35 for the presence of the VSV-G envelope
rotein before induction with ponasterone A and on days
through 4 after induction. A Western blot demonstrating
he inducible expression pattern of the VSV-G envelope
rotein is displayed in Fig. 2C. A high level of expression
f VSV-G occurred only after addition of the inducer and
ersisted for at least 4 days. A high level of VSV-G
roduction following the addition of ponasterone A pre-
eded that of p24 and reverse transcriptase activity de-
pite all vectors being under control of an identical ec-
ysone promoter. This lag in Gag/Pol protein product
FIG. 2. Expression of viral proteins. (A) Induction of p24gag expres-
sion. Supernatant from REr1.35 packaging cells was collected on Day
0 prior to induction with ponasterone A and on days 1 through 4
postinduction. The amount of p24gag in each sample was determined
sing a commercial ELISA kit. (B) Upregulation of RT expression.
upernatant samples from REr1.35 packaging cells were taken prior to
nduction and on days 1 through 4 postinduction followed by measure-
ent of RT activity as described under Materials and Methods. (C)
estern blot analysis of inducible VSV-G expression. Cell lysates were
arvested from uninduced (Day 0) and induced (Day 1 through 4)
Er1.35 cells and total protein was electrophoresed through a 10%
DS–polyacrylamide gel. After transfer, the membrane was probed with
mouse monoclonal antibody specific for VSV-G as outlined under
aterials and Methods. The position of the VSV-G protein is indicated
y the arrow.xpression from pEcgpr is likely owing to a dependence










80 PACCHIA ET AL.two induction phases are required for Gag/Pol produc-
tion: Rev production must happen first, followed by initi-
ation of Gag/Pol expression. This two-phase induction
would seem to account for the different kinetics of ex-
pression of VSV-G versus Gag/Pol. In any event, the
complete absence of viral protein production before in-
duction with ponasterone A paired with the rapid onset
and abundant yield subsequent to induction demon-
strates the tight regulation and high level of protein
expression that can be achieved using the ecdysone-
inducible system.
Production of lentiviral vectors from REr1.35
Most of the previously reported packaging cell sys-
tems depend on the transcriptional transactivator Tat in
order to achieve high-level transcription of the viral ge-
nome and transgene from the HIV-1 LTR. However, it has
been shown that Tat is dispensable for virus production
provided there is a high enough level of transcription of
the viral genome from a constitutive promoter and any
genes of interest are expressed from a heterologous
promoter (Kim et al., 1998; Dull et al., 1998). Taking this
into consideration, we created a Tat-independent trans-
fer vector for inclusion in our accessory null system. The
U3 in the 59 LTR of the transfer vector pCHSGIP (Fig. 1)
was replaced with the constitutive immediate-early en-
hancer/promoter of human cytomegalovirus (CMV) while
GFP and the puromycin resistance gene are expressed
from a separate SNV-U3 promoter within the body of the
vector.
To generate the stable producer cell line, the pCHSGIP
TABLE 1




1 1.8 6 2.6 3 102
4.1 6 3.1 3 103
2 1.8 6 0.2 3 104
3.1 6 0.5 3 104
3 4.0 6 0.4 3 104
1.0 6 2.5 3 105
4 1.0 6 1.4 3 105
1.0 6 0.3 3 105
5 1.8 6 0.2 3 105
6.7 6 2.2 3 104
a Viral titers were determined by infecting dividing HeLa cells as
escribed under Materials and Methods. The titer was calculated by
ounting the number of GFP1 puror colonies, dividing by the volume of
the inoculum (in milliliters), and multiplying the result by the dilution
factor. Viral titers are expressed as mean infection units per milliliter 6
SD.
b Days indicate period of time after addition of ponasterone A during
m
d
which viral titer was examined. Day 0 represents supernatant from
uninduced cells.plasmid was transfected into REr1.35 cells and 25 GFP-
positive, puromycin-resistant clones were isolated. Con-
stitutive expression of GFP from pCHSGIP facilitated
selection of stable cell clones since the REr1.35 cells
were uninduced at the time of transfection and hence,
the GFP harbored by the pEcVIGhyg plasmid was not
being transcribed. Each of the isolated cell clones was
examined for their capacity to produce high-titer virus by
culturing in medium containing 10 mM ponasterone A.
After 48 h, the culture medium was replaced with fresh
medium containing a second dose of 10 mM ponaster-
ne A. Forty-eight hours after the second addition of
onasterone A, conditioned medium was harvested and
sed to infect target cells. Based on its preliminary titer
f 0.4 3 105, the cell clone REr1.35.30 was chosen as the
stable, inducible lentiviral vector producer cell line.
To obtain the highest titer virus possible, we decided
to further characterize the producer cell line by determin-
ing the optimal time for viral harvest after induction.
Conditioned supernatant from REr1.35.30 was collected
before and at successive time points after induction with
ponasterone A (Table 1). Maximal titers observed 4 days
postinduction ranged from 0.8 3 105 to 1.2 3 105 IU/ml.
Virus produced from this cell line is pseudotyped with
the VSV-G envelope protein, making it amenable to con-
centration by ultracentrifugation. We examined this po-
tential for concentration by collecting and pooling con-
ditioned supernatant from REr1.35.30 4 days after induc-
tion and subjecting it to two consecutive rounds of
ultracentrifugation as outlined under Materials and
Methods. With recoveries averaging 74%, the
pseudotyped virus produced from REr1.35.50 could be
concentrated up to 1400-fold to achieve titers upward of
0.8 3 108 IU/ml (Table 2).
Even though the possibility of generating wild-type
IV-1 is virtually nonexistent in our system because the
TABLE 2




1 0.9 6 2.0 3 105 0.2 6 0.4 3 108
2 0.8 6 1.2 3 105 0.6 6 0.3 3 108
3 0.4 6 1.7 3 105 0.2 6 0.5 3 108
4 0.3 6 2.3 3 105 0.2 6 0.7 3 108
5 0.6 6 1.6 3 105 0.8 6 0.9 3 108
a Titer values were determined on dividing HeLa cells as described
nder Materials and Methods and are expressed as mean infectious
nits per milliliter 6 SD.
b Conditioned media were filtered and used directly (unconcentrated)
or subjected to two rounds of ultracentrifugation (concentrated) as
described under Materials and Methods.ajority of the HIV-1 genes have been deleted, the pro-













































81LENTIVIRAL PACKAGING CELL SYSTEMbe a liability. Therefore, viral stocks propagated from
REr1.35.30 were tested for the presence of replication-
competent virus by employing three independent meth-
ods: (i) a marker rescue assay that utilizes MRC-CH, a
HeLaT4-based cell line that harbors the CHSGIP provirus
(Fig. 1); (ii) the detection of HIV gag transfer to vector-
ransduced MRC-CH cells by p24gag ELISA; and (iii) a
everse transcriptase assay on supernatant collected
rom vector-transduced MRC-CH cells. The results ob-
ained from all three procedures indicated that condi-
ioned medium produced from the REr1.35.30 cell line
as always free of replication-competent virus (data not
hown).
haracterization of recombinant virus produced from
Er1.35.30
That lentiviral vectors have the ability to transverse the
uclear envelope barrier regardless of the mitotic state
f the target cell is integral for their use in in vivo gene
elivery. The efficiency with which vector virus produced
rom REr1.35.30 could transduce nondividing cells was
xamined in parallel with a Gibbon ape leukemia virus
GALV)-pseudotyped MLV-based vector and a VSV-G
seudotyped HIV-1-based vector containing accessory
roteins (Adelson et al., manuscript in preparation). All of
he viral vectors harbor the gene for expression of GFP,
hich facilitated scoring infected target cells in the ab-
ence of puromycin selection. HeLa cells that were
FIG. 3. Green fluorescent protein gene transfer to growth-arrested
mages obtained from g-irradiated HeLa cells transduced with virus prorowth arrested at the G2 stage of the cell cycle by
g-irradiation were inoculated with the HIV-1-based or
1
sMLV-based vectors at comparable multiplicities of infec-
tion (m.o.i.). As Fig. 3 demonstrates, virus produced from
REr1.35.30 was able to efficiently infect the nondividing
cells in proportions similar to its VSV-G pseudotyped
HIV-1-based vector counterpart, which harbors acces-
sory proteins (Adelson et al., manuscript in preparation,
ata not shown). In contrast, the MLV-based vector virus
as incapable of gene transfer to the irradiated targets
compare Figs. 3c and 3d). This experiment verifies that
he absence of accessory proteins from our packaging
ell line does not affect the ability of the virus produced
o efficiently infect growth-arrested target cells.
While gene delivery to cells with a low mitotic index is
n important consideration when establishing a lentiviral
ector producer cell line, it is equally important to
chieve a high efficiency of gene transfer. This goal can
e accomplished by concentrating VSV-G pseudotyped
entiviral vectors to yield high-titer virus stocks capable
f transducing a maximal number of target cells. How-
ver, caution must be exercised when estimating trans-
uction efficiencies since it has been reported that con-
entrated VSV-G pseudotyped retroviral vectors may lead
o an artificially elevated efficiency of gene transfer,
rought about by passive protein transfer, or pseudo-
ransduction (Liu et al., 1996; Gallardo et al., 1997). To
emonstrate efficient gene transfer and ensure the ab-
ence of pseudotransduction by GFP, we infected HeLa
ells with virus concentrated from REr1.35.30 (m.o.i. 5
cells. Shown are phase (top) and fluorescence (bottom) microscope
from REr1.35.30 (left) or from an MLV-based packaging cell line (right).0) and maintained them in the absence of puromycin








































































82 PACCHIA ET AL.the targeted HeLa cells were harvested and subjected to
flow cytometric analysis in order to accurately determine
the percentage of GFP1 target cells. We found that the
roportion of GFP1 HeLa cells averaged 28.8% 48 h
postinfection and 36.5% 2 weeks postinfection with GFP
expression persisting for a minimum of 5 weeks (data not
shown). Passive protein transfer should result in a pre-
cipitous decrease in the proportion of GFP1 target cells
because the protein transferred should not persist in any
of their daughter cells. Based on our observations, we
concluded that virus produced from REr1.35.30 can
achieve efficient gene delivery and long-term expression
in the absence of pseudotransduction.
DISCUSSION
Creation of a safe retroviral packaging line that can
produce high-titer, helper-free vector virus is a vital pre-
requisite if the recombinant virus is to be used in a
human gene therapy protocol. Combining HIV-1’s char-
acteristic ability to transverse intact nuclear membranes
with the broad target cell tropism of the VSV-G envelope
affords a packaging system with a good measure of
flexibility since these pseudotyped lentiviral vectors can
be used to deliver an exogenous gene of interest to both
dividing and nondividing cells in a wide variety of tis-
sues. Furthermore, the stability with which the exoge-
nous gene is integrated into the host cell genome and
the duration of its expression make these vectors partic-
ularly attractive as vehicles for in vivo gene delivery. This
report details the establishment of a novel stable lenti-
viral packaging cell line for the production of high-titer
recombinant virus stocks for efficient gene transfer.
We decided to implement an inducible system for virus
production because unregulated expression of VSV-G
and HIV-1 protease has been reported to have cytotoxic
effects (Burns et al., 1993; Jowett et al., 1995; Rogel et al.,
995; Kaplan and Swanstrom, 1991). Moreover, we found
hat constitutive expression of the transcriptional het-
rodimer that drives the ecdysone-inducible system was
asy to establish in the 293T cell background and pro-
ides for rapid and high-level expression of all the pro-
eins required for packaging. Since mammalian cells are
ot responsive to ponasterone A and do not contain the
cdysone receptor, transcription of viral genes placed
nder control of the ecdysone promoter system in the
bsence of the inducer is negligible. In addition, the
ybrid ecdysone response element further minimizes the
ossibility of basal transcription brought about through
he interaction of endogenous mammalian receptors that
ay bind to the natural response element. These char-
cteristics are unique to the ecdysone-inducible system
nd serve to ensure that vector virus is generated only
pon addition of ponasterone A to the producer cells.Elimination of HIV-1 genes that are not essential for
ector production or infectivity facilitates establishment
s
cf a safe packaging cell line for HIV-1 vectors. Indeed,
he results we achieved with our multiply attenuated
ackaging line mirror previous reports that indicate that
he 293T cell background fully supports efficient lentiviral
ector production even in the absence of the Vif, Vpr, Vpu,
nd Nef accessory proteins (Kafri et al., 1997; Kim et al.,
998; Zufferey et al., 1997). Transcription of full-length
enomic RNA from the HIV-1 LTR promoter is contingent
pon the Tat regulatory protein. While this dependence
an act as a safety measure by prohibiting production of
iral genomic RNA from the provirus in the genome of the
arget cell, transcription and packaging of the transduc-
ng vector cannot occur in its absence. In order to elim-
nate this protein from our system, a Tat-independent
ransducing vector was created by substituting the 59 U3
romoter region with the strong constitutive CMV pro-
oter and placing the selectable markers under control
f a separate internal promoter. HIV-1 encodes another
egulatory protein, Rev, which binds to a Rev-response
lement (RRE) found on the viral mRNA and functions to
romote cytoplasmic transport of unspliced and partially
pliced mRNA molecules. A system devoid of Rev/RRE is
everely impaired in viral production unless an alternate
NA transport mechanism is provided. We attempted to
stablish a Rev-independent vector system based on the
nowledge that the Rev/RRE tandem could be substi-
uted for by a cis-acting constitutive transport element
CTE) from the Mason–Pfizer monkey virus (MPMV) (Bray
t al., 1994; Srinivasakumar and Schuening, 1999; Srini-
asakumar et al., 1997). Single or multiple copies of the
TE corresponding to nucleotides 8007–8240 of the
PMV genome were incorporated into the constructs
escribed earlier in this report and the resulting stable
ell lines were tested for virus propagation. Our results
arallel those reported by others in that protein produc-
ion and viral titers were exceeding low when compared
o REr1.35.30, which makes use of Rev-mediated trans-
ort (Gasmi et al., 1999; Kim et al., 1998). While it is
onceivable that the cellular factors involved in shuttling
he CTE-containing mRNAs are limiting in the 293T cell
ackground, it is also possible that the inefficiency of the
TE is idiosyncratic to this mechanism of transport.
ased on these findings, Rev seems important for profi-
ient vector virus production from our current packaging
ell system.
Lentiviruses such as HIV-1 have the ability to infect
nd integrate into the genome of a nondividing cell. This
nique characteristic is advantageous since many po-
ential target tissues contain cells that have a low mitotic
ndex. In this report, we have been able to demonstrate
hat even without tat, vif, vpr, vpu, and nef our lentiviral
ackaging cell line retains the capability to transduce
rowth-arrested target cells, lending further credence to
rior observations that, at least for these target cells,
ufficient signals for transport of the HIV-1 preintegration
omplex across the intact nuclear membrane reside
83LENTIVIRAL PACKAGING CELL SYSTEMwithin the HIV-1 Gag and Pol proteins. Moreover, the
efficiency and stability with which the vector DNA is
integrated into the host cell genome will prove to be both
integral and beneficial for long-term expression of the
transgene from this recipient cell.
Several features of the lentiviral packaging cell line
described here represent significant advantages for its
use in gene therapeutics. (i) The packaging construct,
the VSV-G envelope plasmid, and the transducing vector
are introduced sequentially, and stable clones are se-
lected and screened after each introduction. This pro-
cess not only reduces the possibility of nonhomologous
recombination that may occur during transfection of mul-
tiple plasmids, but also allows us to reproducibly prop-
agate vector virus. (ii) The incorporation of the ecdysone
system allows us to control the transcription of the HIV-1
gag, pol, and rev genes as well as the VSV-G envelope in
order to circumvent any risk of cytotoxicity that would
result from their constitutive expression. Since transcrip-
tion is triggered only in the presence of the inducer, high
levels of expression of potentially cytopathic gene prod-
ucts such as HIV-1 protease and VSV-G are quickly and
readily achievable and vector virus production is both
tightly and temporally regulated. (iii) Pseudotyped recom-
binant virions can be concentrated to yield very-high-titer
stocks as the VSV-G envelope is particularly resistant to
the shearing forces incurred during ultracentrifugation.
The resulting high-titer virus stocks can provide for a
high efficiency of gene delivery, an important consider-
ation for in vivo gene therapy protocols. (iv) Most impor-
tantly, the absence of the HIV-1 accessory and Tat pro-
teins combined with a lack of homology between the
viral coding sequences of the packaging construct and
the envelope plasmid obviates the possibility of unto-
ward generation of replication-competent HIV-1 recom-
binants. As noted above, vector virus produced from this
system has consistently tested negative for the presence
of replication-competent virus.
A recent report has described the establishment of a
stable, accessory-null, tetracycline-repressible packag-
ing cell line for lentiviral vectors (Klages et al., 2000). In
previous publications, our laboratory has likewise dem-
onstrated the utility of the tetracycline-regulated system
in generating packaging cell lines for studies of HIV-1
biology (Yu et al., 1996; Kaul et al., 1998). In our current
endeavor, we have found the ecdysone-inducible system
to be an attractive and improved alternative to tetracy-
cline for use in a conditional viral gene expression sys-
tem owing to its lower basal expression and greater level
of induction as well as efficient and rapid penetrance
and clearance of the inducer, ponasterone A (No et al.,
1996; unpublished data). Moreover, the ecdysone induc-
tion process is precise and the production of vector virus
is rapid, reaching a peak in 3 to 5 days rather than up to
14 days as previously reported for tetracycline-respon-
sive systems. In the report by Klages et al. (2000), virus
s
tproduced by a transient multiple cotransfection is used
to infect the packaging cells for 4 consecutive days.
Subsequent to these infections, tetracycline is withdrawn
and the recombinant vector virus of interest can be
harvested 7 to 10 days after the induction. In addition to
the fact that it would take a minimum of 2 weeks to
collect vector virus stocks, the cotransfection with mul-
tiple plasmids creates an environment for nonhomolo-
gous as well as homologous recombination. Without a
stable, characterized, virus-producing cell system, a sa-
lient potential to produce either replication-competent
virus or viral vectors of questionable genetic composition
still remains.
The major characteristics of a successful packaging
cell system are production of high-titer vector virus ca-
pable of infecting a broad range of target cells regard-
less of their mitotic state and establishment of a provirus
that will provide long-term expression of a transgene of
interest. In addition, the biosafety of these lentiviral vec-
tor systems is of paramount concern in the area of gene
therapeutics. It is vitally important that a cell line that
provides recombinant virus for in vivo applications will
not produce virus capable of independent replication.
The ecdysone-inducible system for the efficient produc-
tion of lentiviral vectors we currently describe can effi-
ciently transduce both dividing and nondividing cells
while deactivating viral replication and pathogenic po-
tential. Improvements to the current system, including
self-inactivating transducing vectors and alternative




pVgRXR and the pIND expression vector are part of the
Ecdysone-Inducible Expression Kit (Invitrogen K1001-01).
pVgRXR encodes the heterodimeric ecdysone receptor
subunits VgEcR and RXR. To construct pEcVIGhyg, the
VSV-G envelope coding sequence was linked to the GFP
by an IRES and was placed under transcriptional control
of the inducible ecdysone promoter by cloning into pIND.
Plasmid pEcgpr was constructed from pJJO1DBglII, a
proviral clone of the LAI strain of HIV-1, which contains
deletions in the encapsidation sequence from nucleo-
tides 241–253 and 295–328 and a BglII deletion between
nucleotides 6630 and 7215 that prevents expression of
the env gene (a gift from Dr. Julian J. O’Rear). An 8.3-kb
BssHII–SacI fragment from JJO1DBglII was ligated into
the EcoRV site of pIND to generate pJS. pJS was digested
with NdeI and XhoI, which created a deletion between
nucleotides 4710 and 9170. The 5.4-kb NdeI–XhoI pJS
backbone was ligated to a 167-bp polymerase chain
reaction product containing the first exon of rev with itsplice sites and a 1.9-kb NdeI–XhoI fragment containing
































84 PACCHIA ET AL.tains ecdysone-inducible open reading frames for Gag,
Pol, and Rev but has mutations, deletions, or disruptions
in the packaging signal (c), primer-binding site (pbs),
tat, vif, vpr, vpu, env, and nef. The transducing vector
pCHSGIP is derived from pHIV-GIP (Kaul et al., 1998),
which contains a 5.8-kb deletion from nucleotides 961–
6854 of pLAI3 (a gift from Dr. Michael Emerman), leaving
approximately 620 bp of gag and 1.4 kb that encom-
passes a fragment of the env gene and the RRE. To
construct the HIV-1-based retrovirus vector pCHSGIP, a
630-bp fragment containing the CMV promoter was pre-
cisely fused to the R-U5-pbs region of the 59 LTR of
HIV-GIP by PCR and cloned into pGEM-T Easy (Pro-
ega A1360). An XbaI–HaeII fragment containing the
MV-LTR fusion was ligated to 1.9-kb HaeII–BamHI and
.9-kb BamHI–SpeI fragments from pHIV-GIP to yield
CHSGIP.
ackaging cell line generation
293T (human embryonic kidney) cells (DuBridge et al.,
987), HeLaT4 cells (a gift from Dr. Michael Emerman),
nd HeLa cells (Jones et al., 1971) were maintained in a
% CO2 atmosphere at 37°C in minimal essential me-
dium (MEM) containing Earle’s salts and L-glutamine
(Gibco BRL 11095-080) and supplemented with 10% fetal
bovine serum (Hyclone), 103 MEM nonessential amino
acids (Gibco BRL 11140-050), 250 units/ml penicillin, and
250 mg/ml streptomycin (Gibco BRL 15070-063). All trans-
ections were via the modified calcium phosphate pre-
ipitation method (Gorman, 1985). To generate a stable
ell line REr that conditionally expresses the het-
rodimeric ecdysone receptor subunits and gag, pol, and
ev, 293T cells were cotransfected with 10 mg pEcgpr
and 25 ng pVgRXR, which harbors the Zeocin resistance
gene. Transfected cells were selected for resistance to
50 mg/ml Zeocin (Invitrogen R250-01) and individual col-
onies were screened for reverse transcriptase (RT) ac-
tivity according to standard protocol (Willey et al., 1988)
before and after induction with 10 mM ponasterone A
(Invitrogen H101-01). REr clones that exhibited the high-
est level of inducible RT activity were then transfected
with 10 mg pEcVIGhyg and selected for hygromycin re-
istance (150 mg/ml) (Calbiochem). Hygromycin-resistant
clones were split into two dishes in order to concomi-
tantly maintain and test each clone for ponasterone A
responsiveness. A high level of GFP expression in the
presence of ponasterone A as determined by fluores-
cence microscopy (Zeiss Axiovert S100 inverted micro-
scope) delineated the clone REr1.35, which represents
the packaging cell line for the HIV-1 vector, pCHSGIP.
The lentiviral producer cell line REr1.35.30 was estab-
lished by transfection of 10 mg of the transfer vector
CHSGIP into REr1.35, selection with 1 mg/ml puromycin
(Sigma), and evaluation of viral titer according to the
protocol described below.Virus production, titer, and concentration
To test the viral titer, 3 3 106 REr1.35.30 cells were
lated in 100-mm tissue culture dishes (Falcon 3003) in
0% MEM. Forty-eight hours later, the medium was
hanged to 10% MEM containing 10 mM ponasterone A.
On day 2 postinduction, the cells were refed with 10%
MEM 1 10 mM ponasterone A. Supernatant was har-
vested on day 4 postinduction and viral titers were de-
termined on HeLa cells as follows. Twenty-four hours
before infection, HeLa cells were plated at a density of
3 3 105 cells/60-mm tissue culture dish (Falcon 3002) in
0% MEM. On the day of infection, viral supernatant was
ollected and filtered through a 0.45-mm pore-size filter.
Serial dilutions of the conditioned medium were made in
10% MEM and added to the HeLa cells in the presence
of 50 mg/ml polybrene (Sigma). The infections were
gently rocked at 20-min intervals during their incubation
at 37°C. After 2 h, the virus/polybrene solution was
aspirated and the cells were refed with 10% MEM. Trans-
duced cells were selected for puromycin resistance (1
mg/ml) 24 h after the infection. The puromycin-resistant
titer was corroborated by counting the number of GFP-
positive target cells using fluorescence microscopy.
To produce concentrated viral stocks, 6 3 106
REr1.35.30 cells were plated in 150-mm tissue culture
dishes (Falcon 3025) in 10% MEM. Forty-eight hours later,
the medium was changed to 10% MEM containing 10 mM
ponasterone A. Two days postinduction, the medium was
replaced with fresh 10% MEM 1 10 mM ponasterone A.
Conditioned medium was collected on day 4 postinduc-
tion, passed through a 0.45-mm pore-size filter, and ul-
racentrifuged at 4°C in a Beckman 45Ti rotor at 50,000g
or 1.5 h. The viral pellet was resuspended in 10% MEM
nd subjected to a second ultracentrifugation at 4°C in
he Beckman 45Ti rotor at 50,000g for 1.5 h. The resulting
iral pellet was resuspended in 10% MEM. Fresh con-
entrated viral supernatant was used to transduce either
ividing or nondividing HeLa cells at a multiplicity of
nfection according to the method described below. Un-
sed supernatant was stored at 270°C.
IV-1 p24gag ELISA
The levels of p24 protein in samples of unconditioned
(uninduced) or conditioned (days 1 through 4 postinduc-
tion) medium from REr1.35 cells were determined by
ELISA using a p24 ELISA kit according to the manufac-
turer’s protocol (NEN Life Science Products).
Reverse transcriptase assay
Supernatant was collected from REr1.35 cells prior to
induction and on days 1 through 4 after the addition of
ponasterone A. RT activity was detected using a stan-
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Uninduced and induced REr1.35 cells were removed
from 100-mm plates by treatment with trypsin, pelleted,
washed three times with phosphate-buffered saline, and
resuspended in lysis buffer [50 mM Tris–HCl (pH 7.5), 150
mM NaCl, 5 mM EDTA, 1% NP-40, 10% glycerol] contain-
ing a protease inhibitor cocktail (Sigma P8340). Total
cellular protein was quantified by using the BCA Protein
Assay (Pierce). Thirty micrograms of total cellular protein
were denatured by boiling for 5 min in loading buffer
containing 0.2 M DTT. The proteins were separated by
10% SDS–PAGE and blotted onto polyvinylidene difluo-
ride membrane (NEN Life Science Products). After block-
ing with 5% nonfat milk in TBS-T [150 mM NaCl, 50 mM
Tris (pH 7.4), 0.1% Tween 20] for 1 h, the blots were
incubated with mouse monoclonal anti-VSV-G (Sigma
V5507) for 1 h at room temperature. The blots were
washed with TBS-T and then incubated with sheep anti-
mouse immunoglobulin conjugated to horseradish per-
oxidase (Jackson ImmunoResearch Laboratories) for 1 h
at room temperature. After washing, protein bands were
detected using the Renaissance chemiluminescence re-
agent as described by the manufacturer (NEN Life Sci-
ence Products).
High m.o.i. transduction of dividing and nondividing
cells
One day prior to infection, dividing HeLa cells were
plated in 10% MEM in a 24-well plate at a density of 104
cells/well. Nondividing cells were generated 1 day prior
to infection by trypsinizing and resuspending HeLa cells
in 1 ml of 10% MEM in a 15-ml tube (Falcon 2059). After
exposure to 4000 rad of g-irradiation, the cells were
pelleted, diluted with fresh 10% MEM, and plated at a
density of 5 3 104 cells/well of a 24-well plate. The
ollowing day, 105 virions were used to inoculate the
dividing (m.o.i. 5 10) and irradiated HeLa cells (m.o.i. 5
2) in the presence of 50 mg/ml polybrene at 37°C for 2 h.
After the incubation, the virus/polybrene solution was
aspirated and replaced with 10% MEM. In the absence of
puromycin selection, fluorescence microscopy was used
to assess GFP gene delivery to the dividing and nondi-
viding HeLa cells.
Assays for replication-competent virus
(i) Marker rescue assay. To generate the marker res-
cue cell line MRC-CH, HeLaT4 cells were transduced
with vector virus produced from REr1.35.30 and placed
on puromycin selection to ensure that each cell harbored
at least one copy of the CHSGIP provirus. The marker
rescue assay was carried out as follows: Using the
protocol described for virus titration given above,
MRC-CH cells were transduced with concentrated vector
stock and passaged for 4 weeks in the absence ofantibiotic selection. After such time, conditioned super-
natants were filtered through a 0.45-mm pore-size filter
and used undiluted to infect virgin HeLa cells using the
same protocol. The transduced HeLa cells were main-
tained in the absence of selection and were subse-
quently scored for GFP expression using fluorescence
microscopy. To demonstrate that the integrated provirus
was capable of being rescued, supernatant containing
wild-type HIV-1LAI was used to infect MRC-CH cells ac-
ording to the protocol described above. After 3 weeks of
assage in the absence of antibiotic selection, condi-
ioned supernatant from the transduced MRC-CH cells
as harvested, passed through a 0.45-mm pore-size fil-
ter, and used to infect fresh HeLaT4 cells. Fluorescence
microscopic examination of the transduced HeLaT4 cells
revealed numerous GFP1 cells. This positive control en-
sured that the provirus could be rescued and, therefore,
replication-competent virus would be detected with this
system. Vector stocks are considered replication-incom-
petent when no GFP1 cells are detected.
(ii) HIV gag transfer assay. Supernatant samples from
MRC-CH cells inoculated with virus stock were har-
vested after 2 and 4 weeks of passage in culture. The
concentration of p24gag in these supernatants was mea-
sured by ELISA using a p24 ELISA kit according to the
manufacturer’s protocol (NEN Life Science Products).
Virus preparations are considered helper free when the
p24 concentration falls below the detection threshold,
which, for this assay, was determined to be $1.2 pg/ml.
(iii) Reverse transcriptase assay. HeLa cells previously
incubated with supernatant from transduced MRC-CH
cells were passaged for 4 weeks in culture and the
supernatant was tested for the presence of RT using the
standard procedure (Willey et al., 1988).
Flow cytometric analysis
Transduced HeLa cells were trypsinized, washed
twice with PBS, and resuspended in 0.3 ml PBS. Flow
cytometry was performed using an EPICS Profile II
(Coulter Corp.) outfitted with the Elite program (version
4.01; Coulter Corp.).
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